In this issue:
Selinexor in relapsed/refractory MM and Waldenström’s
Selective nuclear export inhibition with selinexor in relapsed/refractory MM
KRd improves OS in relapsed/ refractory MM
HIV antivirals overcome carfilzomib resistance in MM
Ibrutinib ±dexamethasone for relapsed/refractory MM
Outcome and survival trends in MM during 2008–2015
Denosumab vs. zoledronic acid for treating bone disease in new MM
Bortezomib before and after high-dose therapy in MM
Lenalidomide or bortezomib maintenance in MM in the early SCT setting
Please login below to download this issue (PDF)